Comparative Pharmacology
Head-to-head clinical analysis: CHOLAC versus CLENZ LYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLAC versus CLENZ LYTE.
CHOLAC vs CLENZ-LYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic pH. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
Colon lavage solution that osmotically induces diarrhea to cleanse the colon.
15-30 mL (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 mL/day. For hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Oral: 4 L (or 240 mL every 10 minutes) administered the evening before colonoscopy; alternatively, 2 L (or 240 mL every 10 minutes) plus 2 L of clear liquids given in split doses (first 1-2 L evening before, remaining in morning of procedure).
None Documented
None Documented
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Not applicable; systemic absorption is negligible (plasma levels below detection limits). Clinical effect is localized to gastrointestinal tract.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Primarily fecal (approximately 95%) as unabsorbed polyethylene glycol; negligible renal excretion (<5%) as intact polymer.
Category C
Category C
Laxative
Laxative